Skip to main content
padlock icon - secure page this page is secure

Long‐term safety and treatment effects of cannabidiol in children and adults with treatment‐resistant epilepsies: Expanded access program results

Buy Article:

$47.00 + tax (Refund Policy)

Since 2014, cannabidiol (CBD) has been administered to patients with treatment‐resistant epilepsies (TREs) in an ongoing expanded‐access program (EAP). We report interim results on the safety and efficacy of CBD in EAP patients treated through December 2016.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: cannabidiol; efficacy; expanded access program; seizures; tolerability; treatmentā€resistant epilepsy

Document Type: Research Article

Publication date: 01 August 2018

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more